As of 8 Nov 2026, Nilo has raised $101M across 1 verified round on record; latest: $101M Series A led by DCVC Bio, Lux Capital and 1 other, announced 8 Oct 2025.
Nilo Therapeutics develops medicines that target neural circuits to restore immune balance in autoimmune and inflammatory disease.
nilotx.comNew YorkBiotech
4 sources
New York City is mentioned for planned laboratories, not as the company’s headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series A [ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $101M | 2025-10-08 | DCVC Bio, Lux Capital, The Column Group | No recent discussion |
4 sources [ VERIFIED · CORRECTED ] read against 1 of 4 sources
New York City is mentioned for planned laboratories, not as the company’s headquarters. | ||||
Nilo Therapeutics develops medicines that target master-regulator brain-body neural circuits to restore immune balance for people with autoimmune and inflammatory diseases.
Nilo is tackling autoimmune and inflammatory diseases with large unmet need by trying to regulate systemic inflammation centrally rather than relying on conventional immunosuppression. Its $101 million Series A is funding New York laboratories, interdisciplinary R&D growth and preclinical programs, while the company is betting that targeting brain-body master-regulator circuits can modulate multiple immune pathways and reduce therapeutic resistance.